BofA raises Mondelez stock price target to $67 on emerging markets

BofA Securities raised Mondelez’s price target to $67 from $65 and lifted FY2026-FY2028 EPS estimates to $3.08, $3.40, and $3.70, citing strong Q1 performance led by 6.3% organic sales growth in emerging markets. First-quarter EPS of $0.67 beat the $0.61 consensus and revenue of $10.08 billion topped estimates, while organic growth of 3.0% exceeded the 0.6% consensus. The tone remains constructive, though the article also notes selective reinvestment and macro uncertainty.

Analysis

MDLZ looks like a quality compounder where the market is rewarding visible top-line resilience, but the next leg of upside is likely to come from mix and reinvestment discipline rather than further estimate beats. The key second-order effect is that management is explicitly choosing to seed 2027 growth by spending through near-term upside, which should cap near-term margin expansion but reduce the probability of a later-stage earnings reset. That makes the stock less of a pure quarter-to-quarter earnings trade and more of a multi-quarter de-rating/re-rating call on whether reinvestment converts into durable share gains.

The biggest beneficiaries are likely emerging-market competitors and local retailers tied to premium snack categories, because Mondelez’s willingness to reinvest signals it sees defendable elasticity in India/Brazil and does not want to cede shelf space. That said, cocoa relief and stabilization in developed markets create a temporary window for margin repair across global packaged foods, so the broader sector can ride this for a few quarters even if category growth remains sluggish. The subtle risk is that if cocoa/input costs keep easing, consensus may overstate the permanence of current pricing power; volume recovery could become harder once the industry cycles easier comps.

From a timing perspective, this is a months-not-days setup: the next catalyst is less another beat and more whether management can show reinvested spend translating into sustained EM share gains by mid-2026. The contrarian angle is that the stock may already be pricing the good news from analysts lifting targets; if organic growth normalizes and reinvestment weighs on near-term EPS, upside may be limited unless there is a clear step-up in 2027 visibility. In other words, the path of least resistance is still positive, but the asymmetry is narrowing as estimates catch up to the current run rate.

Key Decisions for Investors

• Stay long MDLZ but express it as a 6-12 month hold, not a chase: add on any 3-5% pullback while the market digests reinvestment-driven margin drag; downside is likely limited by defensive consumer demand, but upside should be capped until 2027 visibility improves.
• For a relative-value expression, go long MDLZ / short a higher-beta global snack peer with weaker EM exposure over the next 2-3 quarters; MDLZ has the cleaner balance of growth durability and pricing power if EM momentum persists.
• Sell covered calls on existing MDLZ longs into post-earnings strength, targeting 1-2 quarter expiries around the current implied complacency; this harvests premium while the stock transitions from beat-driven to execution-driven.